Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Debio-0932 enters new NSCLC study

Aug. 16, 2012

GMP development of CS-TATI-1 begins

Aug. 16, 2012

Treatment begins in phase I trial of SOR-C13

Aug. 16, 2012

Curegenix reports new lysophospholipid LPA1 receptor antagonists

Aug. 16, 2012

Novel B-raf inhibitors divulged by Boehringer Ingelheim

Aug. 16, 2012

Nerviano Medical Sciences discloses new protein kinase inhibitors

Aug. 16, 2012

Novartis patents new CDK9/cyclin-T1 inhibitors

Aug. 16, 2012

Tarceva approved in Canada for specific NSCLC subtype

Aug. 14, 2012

New E.U. approval for Votrient

Aug. 14, 2012

Nagasaki University reports new candidate anticancer products

Aug. 14, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...